Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

PALI

Palisade Bio (PALI)

Palisade Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PALI
DateTimeSourceHeadlineSymbolCompany
12/17/20245:30PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PALIPalisade Bio Inc
12/17/20245:29PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PALIPalisade Bio Inc
12/17/20245:29PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PALIPalisade Bio Inc
12/17/20248:30AMGlobeNewswire Inc.Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory BoardNASDAQ:PALIPalisade Bio Inc
12/17/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PALIPalisade Bio Inc
12/16/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PALIPalisade Bio Inc
12/13/20244:05PMGlobeNewswire Inc.Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq RulesNASDAQ:PALIPalisade Bio Inc
12/13/202410:31AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PALIPalisade Bio Inc
12/13/20249:57AMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PALIPalisade Bio Inc
12/13/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PALIPalisade Bio Inc
12/12/202412:05PMGlobeNewswire Inc.Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq RulesNASDAQ:PALIPalisade Bio Inc
12/09/20245:30PMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:PALIPalisade Bio Inc
12/05/202410:25AMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:PALIPalisade Bio Inc
12/03/20248:15AMGlobeNewswire Inc.Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated SubjectsNASDAQ:PALIPalisade Bio Inc
11/22/20245:10PMEdgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:PALIPalisade Bio Inc
11/22/20244:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
11/22/20244:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
11/21/20242:18PMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:PALIPalisade Bio Inc
11/21/20248:15AMGlobeNewswire Inc.Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)NASDAQ:PALIPalisade Bio Inc
11/14/20243:35PMEdgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:PALIPalisade Bio Inc
11/14/20249:00AMGlobeNewswire Inc.Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) SummitNASDAQ:PALIPalisade Bio Inc
11/12/20248:45AMGlobeNewswire Inc.Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108NASDAQ:PALIPalisade Bio Inc
11/07/20248:30AMGlobeNewswire Inc.Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)NASDAQ:PALIPalisade Bio Inc
10/31/20248:30AMGlobeNewswire Inc.Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative ColitisNASDAQ:PALIPalisade Bio Inc
10/30/20246:05AMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PALIPalisade Bio Inc
10/15/20248:00AMGlobeNewswire Inc.Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific MeetingNASDAQ:PALIPalisade Bio Inc
10/10/20248:30AMGlobeNewswire Inc.Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)NASDAQ:PALIPalisade Bio Inc
10/08/20248:00AMGlobeNewswire Inc.Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLCNASDAQ:PALIPalisade Bio Inc
09/27/20244:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PALIPalisade Bio Inc
09/25/20248:00AMGlobeNewswire Inc.Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative ColitisNASDAQ:PALIPalisade Bio Inc
 Showing the most relevant articles for your search:NASDAQ:PALI